Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Sunday, October 16, 2022

Characteristics and clinical significance of plasma IL‐18, sCD14 and sCD163 levels in patients with HIV‐1 infection

alexandrossfakianakis shared this article with you from Inoreader

Abstract

Background and aim

Biomarkers of monocyte-macrophages activation and inflammation in plasma such as interleukin-18 (IL-18), soluble leukocyte differentiation antigen 14 (sCD14) and sCD163 are associated with disease severity and prognosis in HIV-1 infected patients, however, their relationships with efficacy of antiretroviral therapy (ART) need further investigation. We aimed to characterize and explore the clinical significance of plasma IL-18, sCD14 and sCD163 in this population.

Methods

This was a retrospective cohort study consisting of HIV-1 infected patients enrolled in a randomized, controlled, open-label, non-inferiority trial (ALTERLL study), with follow-up time points including initiation of ART (baseline), 12-, 24- and 48-weeks of treatment. Plasma levels of IL-18, sCD14 and sCD163 were measured using enzyme-linked immunosorbent assay method. Viral suppression was defined as HIV-1 RNA <20 copies/mL.

Results

Among the 193 studied pa tients (median age of 29.0 years, 180 males), IL-18 and sCD163 had U-shaped regression curves and sCD14 had an inverted U-shaped regression curve while virus was decreasing and immune function recovered. Patients with higher levels of IL-18 or lower levels of sCD163 at baseline were less likely to achieve viral suppression at week 12 or week 24 of treatment, respectively. In multivariate analysis, baseline sCD163 ≤500 pg/mL (aOR 0.33, 95%CI 0.16-0.68) was independently associated with lower rate of viral suppression at week 24 of treatment.

Conclusion

We demonstrated different dynamic changes among IL-18, sCD14 and sCD163 after ART. Baseline sCD163 level could be a potential predictor of early virological response to ART. Further validation and mechanistic research are needed.

This article is protected by copyright. All rights reserved.

View on Web

No comments:

Post a Comment